共 640 条
[1]
Gheith O(2015)Diabetic kidney disease: world wide difference of prevalence and risk factors J Nephropharmacol 5 49-56
[2]
Farouk N(2016)Global prevalence of chronic kidney disease—a systematic review and meta-analysis PLoS One 11 1456-1462
[3]
Nampoory N(1993)The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 861-869
[4]
Halim MA(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 e002496-867
[5]
Al-Otaibi T(2021)Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study BMJ Open Diabetes Res Care 9 858-479.e471
[6]
Hill NR(2021)Comparison of adverse kidney outcomes with empagliflozin and linagliptin use in patients with type 2 diabetic patients in a real-world setting Front Pharmacol 12 471-e360
[7]
Fatoba ST(2022)SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes Am J Kidney Dis 79 E351-1517
[8]
Oke JL(2020)Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study Am J Kidney Dis 76 1510-348
[9]
Hirst JA(2020)Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study CMAJ 192 820-1485
[10]
O'Callaghan CA(2020)Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study BMJ 369 340-475